Abstract:Importance: Acute coronary syndrome (ACS) is a major cause of morbidity and mortality in the United States with an annual incidence of approximately 1 million. Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) reduces cardiovascular event rates after ACS. Observations: In 2016, the updated guidelines from the American College of Cardiology/American Heart Association (ACC/AHA) recommended aspirin plus a P2Y12 inhibitor for at least 12 months for patients with ACS. Since these recommendations were published, new randomized clinical trials have studied different regimens and durations of antiplatelet therapy. Recommendations vary according to the risk of bleeding. If bleeding risk is low, prolonged DAPT may be considered, although the optimal duration of prolonged DAPT beyond 1 year is not well established. If bleeding risk is high, shorter duration (ie, 3-6 months) of DAPT may be reasonable. A high risk of bleeding traditionally is defined as a 1-year risk of serious bleeding (either fatal or associated with a ≥3-g/dL drop in hemoglobin) of at least 4% or a risk of an intracranial hemorrhage of at least 1%. Patients at higher risk are 65 years old or older; have low body weight (BMI <18.5), diabetes, or prior bleeding; or take oral anticoagulants. The newest P2Y12 inhibitors, prasugrel and ticagrelor, are more potent, with high on-treatment residual platelet reactivity of about 3% vs 30% to 40% with clopidogrel and act within 30 minutes compared with 2 hours for clopidogrel. Clinicians should avoid prescribing prasugrel to patients with a history of stroke or transient ischemic attack because of an increased risk of cerebrovascular events (6.5% vs 1.2% with clopidogrel, P = .002) and should avoid prescribing it to patients older than 75 years or who weigh less than 60 kg. The ISAR-REACT-5 trial found that prasugrel reduced rates of death, myocardial infarction, or stroke at 1 year compared with ticagrelor among patients with ACS undergoing percutaneous coronary intervention (9.3% vs 6.9%, P = .006) with no significant difference in bleeding. Recent trials suggested that discontinuing aspirin rather than the P2Y12 inhibitor may be associated with better outcomes. Conclusions and relevance: Dual antiplatelet therapy reduces rates of cardiovascular events in patients with acute coronary syndrome. Specific combinations and duration of dual antiplatelet therapy should be based on patient characteristics-risk of bleeding myocardial ischemia.

Advances of antiplatelet therapy in acute coronary syndrome patients accompanied with high risk factors of bleeding and is-chemic events

Safety of Early Antiplatelet Therapy for Non-Cardioembolic Mild Stroke Patients with Thrombocytopenia.

Antiplatelet Therapy and Anticoagulation before, during, and after Acute Coronary Syndrome

Personalised antiplatelet therapies for coronary artery disease: what the future holds

Balancing benefits and risks of oral antiplatelet strategies in patients with coronary artery diseases: an evolving issue.

Clinical research progress of antiplatelet drugs

A Case Study of Initial Antithrombotic Therapy of Atrial Fibrillation and Coronary Heart Disease and Literature Review

In‐Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings from the CCC‐ACS (improving Care for Cardiovascular Disease in China‐Acute Coronary Syndrome) Project

Progress of novel oral antiplatelet medicine in acute coronary syndrome

Antiplatelet therapy for coronary artery disease in 2023: current status and future prospects

Predictors of gastrointestinal bleeding in patients with acute coronary syndrome and the optimal duration of dual antiplatelet therapy

Antiplatelet Therapy for Elderly Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary Syndromes

How to Select Antiplatelet Therapy in Patients with Acute Coronary Syndrome, According to Platelet Function Testing or Pharmacogenomic Testing?

Optimal anti-platelet therapy for older patients with acute coronary syndrome: a network meta-analysis of randomized trials comprising 59,284 older patients

Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review

Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy

Efficacy, Safety, and Role of Antiplatelet Drugs in the Management of Acute Coronary Syndrome: A Comprehensive Review of Literature

In-hospital major bleeding in patients with acute coronary syndrome medically treated with dual anti-platelet therapy: Associated factors and impact on mortality

Research Progress of Antiplatelet Treatment Strategy for Patients with Acute Coronary Syndrome

2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y<sub>12</sub> Receptor Antagonists in the Asia-Pacific Region: Special Populations